|
|
Line 28: |
Line 28: |
| | | |
| </div> | | </div> |
− |
| |
− |
| |
| </div> | | </div> |
| <div class="bevel bl"></div> | | <div class="bevel bl"></div> |
Line 109: |
Line 107: |
| As a result, we obtained a couple of sequences of possible aaRS candidates, which we evaluated, based on a ROSETTA score, and ordered via gene synthesis. | | As a result, we obtained a couple of sequences of possible aaRS candidates, which we evaluated, based on a ROSETTA score, and ordered via gene synthesis. |
| Figure A describes our modeling project as a whole | | Figure A describes our modeling project as a whole |
| + | </div> |
| + | </div> |
| + | <div class="bevel bl"></div> |
| + | </div> |
| | | |
− | </div>
| |
| | | |
| + | <div class="contentbox"> |
| + | <div class="bevel tr"></div> |
| + | <div class="content"> |
| <h3>Introduction</h3> | | <h3>Introduction</h3> |
| <h4>Overview</h4> | | <h4>Overview</h4> |
Line 120: |
Line 124: |
| | | |
| As evaluating an expanded genetic code is a complex task, the practical laboratory work of our project is supplemented by a theoretical approach, involving modeling, simulation, and evaluation on the computerin silico. Specifically, we focused on simulation to designaimed at designing an aaRS tRNA synthetase for the new non-canonical amino acid CBT-ASP. Additionally to CBT, we also simulated the evolution process for the non-canonical amino acid NPA as a validation of our modeling procedure, altough as synthases for this ncAA are known and thus comparable to our in silico result, we can evaluate our modeling procedure. (Vielleicht hier ein wenig schöner) For this purposeOur core challenge was to evolve, the binding pocket must be evolved in a manner which effectively charges the tRNA with the amino acid, thus also recognizing this amino acid specifically. | | As evaluating an expanded genetic code is a complex task, the practical laboratory work of our project is supplemented by a theoretical approach, involving modeling, simulation, and evaluation on the computerin silico. Specifically, we focused on simulation to designaimed at designing an aaRS tRNA synthetase for the new non-canonical amino acid CBT-ASP. Additionally to CBT, we also simulated the evolution process for the non-canonical amino acid NPA as a validation of our modeling procedure, altough as synthases for this ncAA are known and thus comparable to our in silico result, we can evaluate our modeling procedure. (Vielleicht hier ein wenig schöner) For this purposeOur core challenge was to evolve, the binding pocket must be evolved in a manner which effectively charges the tRNA with the amino acid, thus also recognizing this amino acid specifically. |
− | | + | </div> |
− | </div>
| + | |
− | <h4>Method</h4> | + | <h4>Method</h4> |
| <div class ="article"> | | <div class ="article"> |
| We used the open-source software "Rosetta" for the main part of our modeling project, which was introduced at the University of Washington by David Baker in 1997, initially in the context of protein structure prediction. Since then, Rosetta has grown to include numerous modules and is currently widely used in research. In our application, we focus on the Rosetta module called the "Rosetta Enzyme Design Protocol" | | We used the open-source software "Rosetta" for the main part of our modeling project, which was introduced at the University of Washington by David Baker in 1997, initially in the context of protein structure prediction. Since then, Rosetta has grown to include numerous modules and is currently widely used in research. In our application, we focus on the Rosetta module called the "Rosetta Enzyme Design Protocol" |
| | | |
| </div> | | </div> |
| + | </div> |
| + | <div class="bevel bl"></div> |
| + | </div> |
| | | |
| + | <div class="contentbox"> |
| + | <div class="bevel tr"></div> |
| + | <div class="content"> |
| <h3>ROSETTA Enzyme Design</h3> | | <h3>ROSETTA Enzyme Design</h3> |
| <h4>Overview </h4> | | <h4>Overview </h4> |
Line 139: |
Line 149: |
| <p class="figure subtitle"><b>Figure (2): Flowchart Enzym Design Protocol</b><br></p> | | <p class="figure subtitle"><b>Figure (2): Flowchart Enzym Design Protocol</b><br></p> |
| </div> | | </div> |
− |
| |
− |
| |
| </div> | | </div> |
− |
| |
| </div> | | </div> |
| <div class="bevel bl"></div> | | <div class="bevel bl"></div> |
− | | + | </div> |
| | | |
| | | |
Results
Results in silico
We used this algrithm to simulate the evolution of the tyrosyl-tRNA with the amino acids Nitrophenylalanine and CBT-ASP
We obtained 13 synthetase sequences for CBT-ASP, and 43 sequences for NPA, which fit well into the binding site according to the ROSETTA score.
Results in vivo
In order to test the functionality and specificity of our modeled aaRS, we translated a selection of the most promising amino acid sequences into DNA sequences optimized for E.coli and ordered them via gene synthesis. We then used a positive-negative selection system for characterization. The experiment proceeds as follows:
Due to problems with regards to the protein- and salt-concentration, we retransformed the gensyntheses which had been cloned into pSB1C3. In a next step, these syntheses were cotransformed in E.coli(BL21) with our positive selection plasmid.
With regards to CBT2, only the original colony could be transformed. From CBT4 and CBT5, were used each originally isolated clone and its retransformed counterpart.
Due to the IPTC-induced promoter, we used variants without IPTG, and with 5 mM, 10 mM, and 15 mM added IPTS for all plasmids for the kanamycine resistance.
We chose additional variants with regards to the antibiotics; one variant each of kanamycine, kanamycine and chloramphenicole, and kanamycine, chloramphenicole and tetracycline. The number of resulting colonies for each variant are summarized in figure X. Our in vivo results show that our in silico designed enzymes did not lead to a loss of functioning.